| 000 | 01490 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250514024400.0 | ||
| 264 | 0 | _c20041007 | |
| 008 | 200410s 0 0 chi d | ||
| 022 | _a0253-9624 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRuan, Y | |
| 245 | 0 | 0 |
_a[Comparison of subclinical infection rates between vaccinated group with type I inactivated vaccine against hemorrhagic fever and controls]. _h[electronic resource] |
| 260 |
_bZhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine] _cSep 1999 |
||
| 300 |
_a308-10 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Comparative Study; English Abstract; Journal Article; Randomized Controlled Trial | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntibodies, Viral _xblood |
| 650 | 0 | 4 |
_aChina _xepidemiology |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHantaan virus _ximmunology |
| 650 | 0 | 4 |
_aHemorrhagic Fever with Renal Syndrome _xepidemiology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoglobulin G _xblood |
| 650 | 0 | 4 | _aIncidence |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMass Screening |
| 650 | 0 | 4 | _aVaccination |
| 650 | 0 | 4 | _aVaccines, Inactivated |
| 650 | 0 | 4 | _aViral Vaccines |
| 700 | 1 | _aXu, X | |
| 700 | 1 | _aShao, S | |
| 700 | 1 | _aTong, Z | |
| 700 | 1 | _aWeng, S | |
| 700 | 1 | _aZhou, W | |
| 700 | 1 | _aGu, H | |
| 700 | 1 | _aZhu, Z | |
| 700 | 1 | _aXu, Z | |
| 773 | 0 |
_tZhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine] _gvol. 33 _gno. 5 _gp. 308-10 |
|
| 999 |
_c11772296 _d11772296 |
||